淋巴血管侵犯作为唯一不良病理特征时辅助放疗与人乳头瘤病毒阳性口咽鳞状细胞癌生存的关联
该回顾性队列研究查询美国国家癌症数据库2010至2019年接受手术治疗的T1-2、N0-1期HPV阳性口咽鳞状细胞癌患者,评估淋巴血管侵犯和术后放疗与5年总生存的关联。2768例患者中386例(13.9%)有淋巴血管侵犯,其中以淋巴血管侵犯为唯一不良病理特征的220例(57.0%)接受术后放疗,与5年总生存无显著关联(HR 1.13,95%CI 0.65-1.19)。作者认为这类患者可能不需要术后放疗。
要点
- 早期HPV阳性口咽鳞状细胞癌中,淋巴血管侵犯为唯一不良病理特征者57.0%接受术后放疗。
- 术后放疗与5年总生存无显著关联(HR 1.13,95%CI 0.65-1.19)。
- 作者认为这类患者可能不需要术后放疗。
核心结论
- 接受手术治疗的早期HPV阳性口咽鳞状细胞癌患者,若淋巴血管侵犯为唯一不良病理特征,可能不需要术后放疗。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2010至2019年接受手术治疗的T1-2、N0-1期HPV阳性口咽鳞状细胞癌患者,共2768例。
主要发现
- 2768例患者平均年龄59.3岁,2207例(79.7%)为男性,386例(13.9%)有淋巴血管侵犯。
- 以淋巴血管侵犯为唯一不良病理特征的患者中,220例(57.0%)接受术后放疗。
- 术后放疗与5年总生存无显著关联(HR 1.13,95%CI 0.65-1.19)。
临床怎么用
- 作者认为,接受手术治疗的早期HPV阳性口咽鳞状细胞癌患者,若淋巴血管侵犯为唯一不良病理特征,可能不需要术后放疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative radiotherapy radiation therapy (PORT) for early-stage human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) with positive lymphovascular invasion (LVI) has an unclear association with overall survival (OS). METHODS: This retrospective cohort study queried the National Cancer Database for surgically treated, T1-2, N0-1 HPV+ OPSCC from 2010 to 2019. Primary exposures were LVI and PORT, and the main outcome was 5-year OS. Odds ratios and hazard ratios (HR) with 95% confidence intervals (CIs) were generated using multivariable models and Cox proportional hazard models, respectively. RESULTS: Of 2768 patients, average age was 59.3 years, 2207 (79.7%) were male, and 386 (13.9%) had LVI. Of patients with LVI as their sole adverse pathologic feature, 220 (57.0%) received PORT, which was not associated with 5-year OS (HR, 1.13; CI, 0.65-1.19). CONCLUSIONS: Patients with surgically treated, early-stage HPV+ OPSCC and positive LVI as their only pathologic adverse feature may not require PORT.
引用
- Hong SA, Armstrong AT, Snow K, et al. Association of adjuvant radiation and survival in human papilloma virus-positive oropharynx squamous cell carcinoma with lymphovascular invasion as the sole adverse pathologic feature. Head Neck. 2024. PMID: 38511301. doi:10.1002/hed.27740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。